Ionis Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Accrued Liabilities of $4.59 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2017-03-01
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2016-06-30 was -$7.20M, a 120083.33% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2016-03-31 was -$1.93M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2015-12-31 was $3.76M, a 186.89% increase year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2015-09-30 was $589.00K, a 88.41% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2016 was $4.59M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2015 was -$2.35M, a 128.06% decline from fiscal 2014.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2014 was $8.36M, a 24.91% increase from fiscal 2013.
- Ionis Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2013 was $6.69M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2016-12-31 | $4.59M 10-K · filed 2017-03-01 | |||
| 2016-06-30 | -$7.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$9.13M 10-Q · filed 2016-08-09 | -$5.37M derived: sum of 3 quarters · filed 2017-03-01 | -$4.78M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-03-31 | -$1.93M 10-Q · filed 2016-05-05 | $1.83M derived: sum of 2 quarters · filed 2017-03-01 | $2.42M derived: sum of 3 quarters · filed 2017-03-01 | $2.42M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $4.35M derived: sum of 2 quarters · filed 2017-03-01 | $4.36M derived: sum of 3 quarters · filed 2017-03-01 | -$2.35M 10-K · filed 2017-03-01 |
| 2015-09-30 | $589.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $595.00K derived: sum of 2 quarters · filed 2016-08-09 | -$6.11M 10-Q · filed 2015-11-09 | -$4.80M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$6.70M 10-Q · filed 2016-08-09 | -$5.39M derived: sum of 3 quarters · filed 2017-03-01 | -$305.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$6.70M 10-Q · filed 2016-05-05 | -$5.39M derived: sum of 2 quarters · filed 2017-03-01 | -$311.00K derived: sum of 3 quarters · filed 2017-03-01 | -$989.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $6.39M derived: sum of 2 quarters · filed 2017-03-01 | $5.71M derived: sum of 3 quarters · filed 2017-03-01 | $8.36M 10-K · filed 2017-03-01 |
| 2014-09-30 | $5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $4.40M derived: sum of 2 quarters · filed 2015-11-09 | $7.05M 10-Q · filed 2015-11-09 | $13.29M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.97M 10-Q · filed 2015-08-05 | $8.21M derived: sum of 3 quarters · filed 2016-02-26 | $8.79M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $2.64M 10-Q · filed 2015-05-05 | $8.89M derived: sum of 2 quarters · filed 2016-02-26 | $9.47M derived: sum of 3 quarters · filed 2016-02-26 | $6.98M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $6.83M derived: sum of 2 quarters · filed 2016-02-26 | $4.34M derived: sum of 3 quarters · filed 2016-02-26 | $6.69M 10-K · filed 2016-02-26 |
| 2013-09-30 | $578.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$1.91M derived: sum of 2 quarters · filed 2014-11-07 | $443.00K 10-Q · filed 2014-11-07 | |
| 2013-06-30 | -$2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | -$135.00K 10-Q · filed 2014-08-04 | ||
| 2013-03-31 | $2.35M 10-Q · filed 2014-05-06 | |||
| 2012-12-31 | -$3.25M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $6.27M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $1.01M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | $4.32M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $4.92M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |